Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Erythropoietin (EPO) is a glycoprotein hormone primarily produced by the kidneys that stimulates the production of red blood cells in the bone marrow. It binds to the erythropoietin receptor (EpoR) on erythroid progenitor cells, activating the JAK2/STAT5 signaling pathway to promote their survival, proliferation, and differentiation. Recombinant forms of EPO are used therapeutically to treat anemia associated with chronic kidney disease, chemotherapy, and other conditions.
Binds to erythropoietin receptor (EpoR) on erythroid progenitor cells, activating the JAK2/STAT5 signaling pathway to promote survival, proliferation, and differentiation of erythroid precursors into mature red blood cells.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Erythropoietin (EPO).